This project proposes to continue use of a human drug discrimination procedure to conduct comparative evaluations of the discriminative stimulus characteristics, subjective and physiological effects of opioid agonists, antagonists, and mixed agonist/antagonists and to test some of the parameters of the drug discrimination procedure in humans. Animal laboratory data suggest that opioids acting at different receptor sites (e.g., mu- receptors vs. kappa and/or sigma receptors) possess distinctive discriminative stimulus characteristics which permit the use of drug discrimination procedures to classify opioids with respect to their pharmacological profiles of action. Previous work in our laboratory in developing and using a human drug discrimination paradigm has indicated the utility of this procedure for characterizing and for identifying subtle differences among opioids. Also, these studies provide an opportunity to assess the relationship between discriminative stimulus properties of drugs and their subjective effects in humans. In a residential human experimental laboratory volunteers are trained to discriminate between the effects of two active drugs (or drug doses) and saline. Following the successful acquisition of the three-choice discrimination, various doses of the training drugs and/or other test drugs are administered in experimental sessions to determine the similarity of the test drug/dose to the training drugs. Comparisons to test drugs to training drugs is based on the behavioral discrimination data and on descriptive subjective and physiological data collected in each session. In one group of studies (Experiments 1-5), the stimulus properties of various opioids, agonists and mixed agonist-antagonists will be examined when given alone or in combination with an antagonist. Another group of studies (Experiments 6-10) will examine several methodological parameters of drug discrimination including: drug class specificity with parenterally given opioids and orally given opioids; instructional effects; effects of training dose on the discrimination of drug stimulus properties; and the threshold dose for opioid agonist discrimination. These studies will provide valuable data concerning opioid clinical pharmacology, concerning the parameters and determinants of drug discrimination procedures and outcomes, and concerning the relationship of drug discrimination measures to other measures of opioid actions in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004089-06
Application #
3209163
Study Section
Drug Abuse Clinical and Behavioral Research Review Committee (DACB)
Project Start
1985-08-01
Project End
1993-07-31
Budget Start
1990-08-01
Budget End
1991-07-31
Support Year
6
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Preston, K L; Bigelow, G E (2000) Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther 295:114-24
Jones, H E; Bigelow, G E; Preston, K L (1999) Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure. J Pharmacol Exp Ther 289:1350-61
Preston, K L; Bigelow, G E (1998) Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose. Behav Pharmacol 9:533-43
Dykstra, L A; Preston, K L; Bigelow, G E (1997) Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology (Berl) 130:14-27
Preston, K L; Bigelow, G E (1994) Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure. J Pharmacol Exp Ther 271:48-60
Preston, K L; Bigelow, G E (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813-23
Strain, E C; Preston, K L; Liebson, I A et al. (1993) Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther 267:624-34
Strain, E C; Preston, K L; Liebson, I A et al. (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261:985-93
Weinhold, L L; Preston, K L; Farre, M et al. (1992) Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 30:263-74
Bigelow, G E; Preston, K L (1992) Assessment of buprenorphine in a drug discrimination procedure in humans. NIDA Res Monogr 121:28-37

Showing the most recent 10 out of 30 publications